Sensus Healthcare

Sensus Healthcare, Inc. operates as a medical device company, which provides treatments for both oncological and non-oncological skin conditions. The firm's portfolio of treatment devices includes the SRT-100, SRT-100+, and SRT-100 Vision. Its main product superficial radiation therapy (SRT), a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating basal cell and squamous cell skin cancers, and other skin conditions, such as keloids. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman, and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sensus Healthcare reports solid Q4 earnings, eyes growth opportunities

Sensus Healthcare's Q4 2022 earnings call highlighted strong revenue performance, strategic growth initiatives, and a focus on expense management. The company aims to leverage opportunities in technology enhancements, market expansion, and revenue growth while addressing challenges related to net income decline and managing expenses effectively.

Sensus Healthcare adapts to inflation challenges, eyes global expansion

Sensus Healthcare navigated a challenging Q1 2023 marked by inflation impacts, focusing on product demand, cost management, and international expansion to drive future growth.
Despite financial setbacks, the company's innovative SRT system, strategic initiatives, and collaborations position it well to capitalize on opportunities in the radiation oncology market and international territories.
Addressing inflation challenges, securing purchase orders efficiently, and leveraging partnerships with hospitals and pharmaceutical companies are key focus areas for Sensus Healthcare's sustainable growth strategy.

Sensus Healthcare reports Q2 growth, eyes profitability amid market challenges

Sensus Healthcare showed improved performance in Q2 but faced challenges with declining profits and negative EBITDA.
The company's strengths lie in new software introductions, marketing expansions, and AI development for product enhancement.
Opportunities include expected profitability, market recovery signs, international expansion, and investor engagement strategies.
To address challenges, Sensus needs to navigate financial pressures, regulatory hurdles, and competitive dynamics effectively.

Sensus Healthcare reports Q3 revenue decline but eyes international expansion

Sensus Healthcare faced revenue decline in Q3 but remains confident in growth prospects, emphasizing proper business management to mitigate risks.
The company's focus on international expansion and innovative clinic management solutions presents opportunities for future revenue growth and market penetration.
Despite challenges in the industry and competitive landscape, Sensus Healthcare's financial stability and strategic initiatives position it for continued success.

Sensus Healthcare excels in Q4, eyes international expansion and innovative revenue models

Sensus Healthcare's Q4 performance reflects strong sales and financial stability, positioning the company for growth.
Innovative products and new revenue models showcase the company's commitment to market expansion and revenue diversification.
While challenges exist in market expansion and cost control, strategic opportunities in international markets and new models offer avenues for growth.

Sensus Healthcare posts stellar Q1 results, eyes global expansion

Sensus Healthcare delivered outstanding results in Q1 2024, marked by robust revenue growth, operational excellence, and financial strength.
While facing challenges in maintaining growth momentum and navigating international markets, the company's strategic strengths and opportunities position it for continued success.
With a focus on innovation, market expansion, and strategic partnerships, Sensus Healthcare is poised to capitalize on its current momentum and drive future growth.

Sensus Healthcare reports stellar Q3 performance and eyes global expansion

Sensus Healthcare delivered exceptional Q3 2024 results with doubled revenues, strong profitability, and a robust balance sheet.
The company's strategic strengths include key partnerships, technology diversification, and international market progress.
While challenges like sustaining growth and managing costs exist, Sensus is well-positioned to capitalize on opportunities for expansion and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sensus Healthcare, Inc. is a medical device company, which engages in the provision of treatment for both oncological and non-oncological skin conditions. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman, and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.

Sensus Healthcare, Inc. (NASDAQ:SRTS ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Kim Golodetz - Senior Vice President and Principal, Lippert/Heilshorn & Associates Inc. Joe Sardano - Chairman & Chief Executive Officer Javier Rampolla - Chief Financial Officer Conference Call Participants Anthony Vendetti - Maxim Group Operator Good day, ladies and gentlemen, and welcome to the Sensus Healthcare 1Q 2022 Financial Results Conference Call. All lines have been placed on a listen-only mode and the floor will be open for your questions and comments following the presentation.

Sensus Healthcare, Inc. (SRTS) CEO Joe Sardano on Q1 2022 Results - Earnings Call Transcript

Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of 233.33% and 65.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Sensus Healthcare, Inc. (SRTS) Beats Q1 Earnings and Revenue Estimates

If you are looking for stocks that are well positioned to maintain their recent uptrend, Sensus Healthcare, Inc. (SRTS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Here's Why "Trend" Investors Would Love Betting on Sensus Healthcare, Inc. (SRTS)

Sensus Healthcare, Inc. (SRTS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Sensus Healthcare, Inc. (SRTS) Moves 7.3% Higher: Will This Strength Last?

DLH Hlds

Evolution Petroleum

Euroseas

Hudson Technologies

J.Jill

Pangaea Logistics Solutions

Urban One

Despite the dismal start to 2022 for the market, micro-cap stocks like eight still offer significant growth potential for investors. The post 8 Micro-Cap Stocks to Buy for a Calculated Gamble appeared first on InvestorPlace.

8 Micro-Cap Stocks to Buy for a Calculated Gamble

Sensus Healthcare, Inc. (SRTS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Here's Why Sensus Healthcare, Inc. (SRTS) Could be Great Choice for a Bottom Fisher

Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?

Sensus Healthcare, Inc. (SRTS) Just Overtook the 20-Day Moving Average

BOCA RATON, Fla. , March 09, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that management will be presenting at the following investment conferences during March:

Sensus Healthcare to Present at Two Investment Conferences in March

Sensus Healthcare, Inc. (SRTS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

What Makes Sensus Healthcare, Inc. (SRTS) a Good Fit for "Trend Investing"

BOCA RATON, Fla, March 09, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that its Board of Directors has authorized a program to purchase up to $3,000,000 of shares of its Common Stock.

Sensus Healthcare Announces Share Repurchase Program

IVERIC bio Inc

Liquidia Technologies Inc

Biotech has been the worst performing sector of the stock market across the past 12 months.

Learning Lessons From 3 Stocks Flourishing In A Desperate Biotech Bear Market

Sensus Healthcare, Inc. (SRTS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Will Sensus Healthcare, Inc. (SRTS) Gain on Rising Earnings Estimates?

Sensus Healthcare Inc (NASDAQ: SRTS) sold its Sculptura assets to Empyrean Medical Systems for $15 million in cash.  The sale included an inventory of Sculptura systems and parts, in addition to all related intellectual property.

Sensus Healthcare Offloads Sculptura Assets To Focus On Core Dermatology Offerings

Sale permits Sensus to focus on the core dermatology market while providing capital for channel expansion

Sensus Healthcare Sells its Sculptura™ Assets to Empyrean Medical Systems for $15 Million in Cash

Sensus Healthcare, Inc. (SRTS) is on the Move, Here's Why the Trend Could be Sustainable

Sensus Healthcare, Inc. (SRTS) CEO Joe Sardano on Q4 2021 Results - Earnings Call Transcript

Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of 128.57% and 18.31%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Sensus Healthcare, Inc. (SRTS) Beats Q4 Earnings and Revenue Estimates

4Q21 diluted EPS of $0.32 on revenues of $13.0 million up 433% and 156%, respectively

Sensus Healthcare Reports Record Sales and Earnings for the 2021 Fourth Quarter

Michael J. Sardano named President, Christopher Machuzak and Jeffrey Starling named Regional Vice Presidents of Sales Michael J. Sardano named President, Christopher Machuzak and Jeffrey Starling named Regional Vice Presidents of Sales

Sensus Healthcare Prepares Organization for Long-term Growth with Three Promotions

Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?

Sensus Healthcare, Inc. (SRTS) Just Reclaimed the 50-Day Moving Average

BOCA RATON, Fla, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, February 10, 2022 at 4:30 p.m. Eastern time to discuss the financial results for the fourth quarter and full year 2021. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

Sensus Healthcare to Host Fourth Quarter 2021 Financial Results and Business Update Conference Call on February 10, 2022

CBIZ

Horizon

Metropolitan Bank Hld

Ocwen Financial

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are MCB, HBNC, SRTS, OCN and CBZ.

5 Stocks With Recent Price Strength in a Volatile January

ACM Research

Toyota Motor

Vocera Communications

It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Sensus Healthcare (SRTS), Toyota Motor (TM), ACM Research (ACMR) and Vocera (VCRA) are well poised to gain.

Bet on These 4 Low-Beta Stocks to Counter Market Volatility

Sensus Healthcare, Inc. (SRTS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

News for Sensus Healthcare Stock (SRTS)